LTR Pharma (ASX:LTP) WACC %:10.99% (As of Jun. 26, 2026) — Near Median


ASX:LTP LTR Pharma Ltd ASX:LTP
15 GF Score
Price A$0.56
! 1 Warning Sign
View Full Analysis

What is LTR Pharma WACC %?

LTR Pharma ASX:LTP -4.27% 15 WACC % is 10.99% as of Jun. 26, 2026, which is 7% above its 10-year median of 10.23. GuruFocus rates ASX:LTP with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 1,428 Biotechnology companies, LTR Pharma ranks worse than 64.92% on this metric.

As of today (2026-06-26), LTR Pharma's weighted average cost of capital is 10.99%%. LTR Pharma's ROIC % is -1260.33% (calculated using TTM income statement data). LTR Pharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.

For a comprehensive WACC calculation, please access the WACC Calculator.


LTR Pharma  (ASX:LTP) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, LTR Pharma's weighted average cost of capital is 10.99%%. LTR Pharma's ROIC % is -1260.33% (calculated using TTM income statement data). LTR Pharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.


Related Terms

LTR Pharma WACC % Historical Data

* Premium members only.

The historical data trend for LTR Pharma's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma WACC % Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
WACC %
2.50 0.00 0.00 10.24 10.21

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
WACC % Get a 7-Day Free Trial 10.19 10.24 10.31 10.21 10.72

ASX:LTP vs VRTX, REGN, ALNY: WACC % Comparison

For the Biotechnology subindustry, LTR Pharma's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LTR Pharma WACC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's WACC % distribution charts can be found below:

* The bar in red indicates where LTR Pharma's WACC % falls into.


ASX:LTP
15GF Score
LTR Pharma Ltd ASX:LTP
WACC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LTR Pharma WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, LTR Pharma's market capitalization (E) is A$101.795 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Dec. 2025, LTR Pharma's latest one-year semi-annual average Book Value of Debt (D) is A$0 Mil.
a) weight of equity = E / (E + D) = 101.795 / (101.795 + 0) = 1
b) weight of debt = D / (E + D) = 0 / (101.795 + 0) = 0

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.99%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. LTR Pharma's beta cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.99% + 1 * 6% = 10.99%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.
As of Dec. 2025, LTR Pharma's interest expense (positive number) was A$-0 Mil. Its total Book Value of Debt (D) is A$0 Mil.
Cost of Debt = -0 / 0 = %.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0 / -8.95 = 0%.

LTR Pharma's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=1*10.99%+0*%*(1 - 0%)
=10.99%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of 10.99% mean?
LTR Pharma (ASX:LTP) has a WACC % of 10.99% as of Jun. 26, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on LTR Pharma and its competitors. This is near median its historical median of 10.23. Over the past decade, LTR Pharma's WACC % has ranged from 10.21 to 10.99. According to the industry distribution chart, LTR Pharma ranks #927 out of 1428 companies in the Biotechnology industry, placing it in the top 64.9%.
Is LTR Pharma's WACC % too high?
LTR Pharma's current WACC % of 10.99% is near median its 10-year median of 10.23. Over the past 10 years, this metric has ranged from a low of 10.21 to a high of 10.99. The Biotechnology industry median WACC % is 10.03. LTR Pharma's value of 10.99% is 9.6% above this industry median. Based on the distribution chart, LTR Pharma ranks #927 out of 1428 companies in the Biotechnology industry, which is below the industry midpoint. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's WACC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, LTR Pharma ranks #927 out of 1428 companies for WACC %. This places LTR Pharma in the lower half of its industry. The industry median WACC % is 10.03. LTR Pharma's value of 10.99% is 9.6% above this benchmark. Historically, LTR Pharma's own WACC % has ranged from 10.21 to 10.99 over the past decade. While the company's 10-year median is 10.23 vs. the industry median of 10.03, LTR Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Biotechnology company?
The median WACC % among Biotechnology companies is 10.03, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LTR Pharma's current WACC % of 10.99% is 9.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on LTR Pharma and its competitors. For the Biotechnology industry, the median WACC % is 10.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LTR Pharma's current WACC % is 10.99%, which is near median its own 10-year median of 10.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current WACC % of 10.99%. The current WACC % is 10.99%, which is near median its 10-year median of 10.23 and 9.6% above the Biotechnology industry median of 10.03. LTR Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current WACC % is 10.99% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LTR Pharma Business Description

Address 9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score

Get the complete analysis for ASX:LTP

WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.56
Price